Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18080123rdf:typepubmed:Citationlld:pubmed
pubmed-article:18080123lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0225369lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0521339lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0079904lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0623362lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0013081lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0085862lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C1299583lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0538927lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0919336lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C1367731lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C1150587lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C1705632lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C1608386lld:lifeskim
pubmed-article:18080123lifeskim:mentionsumls-concept:C1549571lld:lifeskim
pubmed-article:18080123pubmed:issue8lld:pubmed
pubmed-article:18080123pubmed:dateCreated2008-5-8lld:pubmed
pubmed-article:18080123pubmed:abstractTextThe purpose of this study was to examine the effects of celecoxib on matrix metalloproteinases (MMP-1 and MMP-3), nitric oxide (NO), and the phosphorylation of nuclear factor-kappaB (NF-kappaB) and three mitogen-activated protein kinases (MAPKs), (p38, JNK and ERK) in human articular chondrocytes from normal, osteoarthritis, and rheumatoid arthritis cartilages. Celecoxib at 100 nM reduced the IL-1beta-induced productions of MMP-1, MMP-3, iNOS, and NO, whereas indomethacin at 100 nM showed no effect. The additional stimulation of prostaglandin E2 (PGE2) failed to restore those productions, while the production of PGE2 were reduced by 1 and 10 microM but not 100 nM of celecoxib. The inhibitors of NF-kappaB, JNK and p38, but not ERK, decreased IL-1beta-enhanced MMP-1, MMP-3 and NO production, respectively, and 100 nM celecoxib down-regulated the phosphorylation of NF-kappaB and JNK but has no effect on either p38 or ERK. Celecoxib has inhibitory effects on MMP-1, MMP-3 and NO productions, suggesting the protective roles directly on articular chondrocytes. Despite the COX-2 selectivity, celecoxib affects those productions via not PGE2 but NF-kappaB and JNK MAPK.lld:pubmed
pubmed-article:18080123pubmed:languageenglld:pubmed
pubmed-article:18080123pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:citationSubsetIMlld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080123pubmed:statusMEDLINElld:pubmed
pubmed-article:18080123pubmed:monthJunlld:pubmed
pubmed-article:18080123pubmed:issn0172-8172lld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:NakamuraTTlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:ItoHHlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:YasudaTTlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:AkiyoshiMMlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:NishitaniKKlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:HiramitsuTTlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:TsutsumiRRlld:pubmed
pubmed-article:18080123pubmed:authorpubmed-author:KitaoriTTlld:pubmed
pubmed-article:18080123pubmed:issnTypePrintlld:pubmed
pubmed-article:18080123pubmed:volume28lld:pubmed
pubmed-article:18080123pubmed:ownerNLMlld:pubmed
pubmed-article:18080123pubmed:authorsCompleteYlld:pubmed
pubmed-article:18080123pubmed:pagination727-36lld:pubmed
pubmed-article:18080123pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:meshHeadingpubmed-meshheading:18080123...lld:pubmed
pubmed-article:18080123pubmed:year2008lld:pubmed
pubmed-article:18080123pubmed:articleTitleCelecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes.lld:pubmed
pubmed-article:18080123pubmed:affiliationDepartment of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Sakyo, Kyoto, Japan.lld:pubmed
pubmed-article:18080123pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080123lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080123lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080123lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080123lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080123lld:pubmed